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Abstract
Aims/hypothesis Nicotinamide phosphoribosyltransferase
(NAMPT) is a multifunctional protein potentially involved
in obesity and glucose metabolism. We systematically
studied the association between circulating NAMPT,
obesity, interventions and glucose metabolism and investi-
gated potential underlying inflammatory mechanisms.
Methods Fasting morning NAMPT serum levels were
measured in cohorts of lean vs obese children, cohorts of
intervention by lifestyle, exercise and bariatric surgery, and
during an OGTT. In addition, mRNA expression, protein
production and enzymatic activity of NAMPT were
assessed from isolated leucocytes and subpopulations.
Results Circulating NAMPT was significantly elevated in
obese compared with lean children and declined after
obesity interventions concomitantly with the decline in
BMI, high-sensitivity C-reactive protein (hsCrP) and
leucocyte counts. Circulating NAMPT significantly corre-
lated with glucose metabolism and cardiovascular variables
in univariate analyses, but only the association with glucose
response during an OGTT was independent from BMI. We
therefore assessed the NAMPT dynamic following an oral
glucose load and found a significant decline of NAMPT
levels to 77.0±0.1% as a function of time, and insulin-to-
glucose ratio during an OGTT in obese insulin-resistant
adolescents. Circulating NAMPTwas, however, most strong-
ly associated with leucocyte counts (r=0.46, p<0.001). The
leucocyte count itself determined significantly and indepen-
dently from BMI insulin resistance in multiple regression
analyses. We systematically evaluated NAMPT expression
among several tissues and found that NAMPT was predom-
inantly expressed in leucocytes. In subsequent analyses of
leucocyte subpopulations, we identified higher NAMPT
protein concentrations in lysates of granulocytes and mono-
cytes compared with lymphocytes, whereas granulocytes
secreted highest amounts of NAMPT protein into cell culture
supernatant fractions. We confirmed nicotinamide mono-
nucleotide enzymatic activity of NAMPT in all lysates
and supernatant fractions. In monocytes, NAMPT release
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DOI 10.1007/s00125-010-2042-zwas significantly stimulated by lipopolysaccharide (LPS)
exposure.
Conclusions Leucocytes are a major source of enzymati-
cally active NAMPT, which may serve as a biomarker or
even mediator linking obesity, inflammation and insulin
resistance.
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Visfatin
Abbreviations
BG Blood glucose
CM Culture medium
EPC Endothelial progenitor cells
hsCrP High-sensitivity C-reactive protein
IMT Intima–media thickness
ISI Insulin sensitivity index
LPS Lipopolysaccharide
NAMPT Nicotinamide phosphoribosyltransferase
NMN Nicotinamide mononucleotide
PBEF Pre-B cell colony enhancing factor
RHI Reactive hyperaemia index
SDS Standarddeviationscore(synonymousforzscore)
WBC White blood cell
Introduction
Nicotinamide phosphoribosyltransferase (NAMPT), for-
merly known as visfatin or pre-B cell colony enhancing
factor (PBEF), is a protein that has been implicated in
various pathophysiological conditions, although some of
these ascribed features are controversial and are still being
discussed. Originally, NAMPT had been identified as PBEF
[1], a cytokine capable of stimulating the maturation of B
cell precursors. NAMPT attracted most attention, however,
when it was re-discovered as an adipocytokine named
‘visfatin’ and claimed to be predominantly secreted from
visceral adipose tissue, exerting insulin-like actions [2].
More recently, NAMPT has been identified as the crucial
NAD biosynthetic enzyme [3] and thereby to play an
important role in the regulation of cellular metabolism and
insulin secretion [4, 5].
So far, clinical studies in adults have provided contro-
versial findings concerning the role of NAMPT in obesity
and glucose metabolism [6], with positive, negative or no
associations found [7–10]. In addition, knowledge of the
main origin of NAMPT is still elusive [11, 12]. Neverthe-
less, no matter which potential NAMPT function is
considered (NAD biosynthetic enzyme, pro-inflammatory
cytokine and/or adipocytokine), NAMPT may have acute
as well as chronic associations with obesity and may
influence major metabolic functions. In particular, the direct
interactions with sirtuin-1 (SIRT1), a key mediator that
coordinates metabolic responses to nutritional availability,
are of interest [13, 14].
Paediatric cohorts allow a less biased exploration of the
clinical context and potential underlying mechanisms link-
ing NAMPT with obesity and glucose metabolism, as they
are less confounded by co-morbidities and their treatment
than adult cohorts. Studies in children have indeed revealed
that circulating NAMPT was elevated in obesity but failed
to detect a direct association with BMI [15, 16].
In this study, we not only provide clinical evidence of
the association of NAMPT with obesity and related
metabolic and cardiovascular sequelae, but also show that
NAMPT is acutely downregulated after glucose provoca-
tion. In particular, we identify leucocytes as a major source
of enzymatically active NAMPT and reveal that the
association of circulating NAMPT with leucocyte count
outranges that with obesity.
Methods
Cohort and patient characteristics
Leipzig Schoolchildren cohort This is a representative
cohort of the Leipzig paediatric population with detailed
characterisation of anthropometric and biochemical varia-
bles of physical and pubertal maturation [17]. We have
selected 134 children that have been previously evaluated
for the dynamics of adipocytokines during pubertal devel-
opment (see Electronic supplementary material [ESM]
Table 1)[ 18].
Leipzig Atherobesity Childhood cohort We recruited 86
obese white children and adolescents and 70 lean controls
of similar age, sex and pubertal stage (ESM Table 2).
Fasting blood samples were obtained at 08:00 hours and
were immediately centrifuged, aliquoted and stored at
−80°C. Metabolic variables were analysed by a certified
laboratory. Insulin and C-peptide were measured using the
Liaison C-peptide and insulin luminescence immunoassay
on the Liaison analyzer (DiaSorin, Saluggia, Italy).
Analytical sensitivity of these test systems was 1.2 and
3 pmol/l, respectively. Mean intra- and interassay coef-
ficients of variation were below 4.1% for insulin and
4.4% for C-peptide.
An OGTT was performed in all participants. HOMA-IR
[19] and Matsuda insulin sensitivity index (ISI) [20] were
calculated as measures of insulin sensitivity. Ambulatory
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Labs Medical Inc., Redmond, USA); a recording was
considered successful if >80% of readings were valid.
Endothelial function was evaluated by the reactive hyper-
aemia index (RHI), and intima media thickness (IMT) by
high-resolution B-mode ultrasound as described previously
[21].
Lifestyle intervention cohort Thirty-six obese children
(ESM Table 3) completed the 1-year lifestyle intervention
‘Obeldicks’ as described in detail elsewhere [22].
Bariatric surgery intervention cohort Fourteen extremely
obese patients (ten adults, four adolescents; ESM Table 3)
were subjected to bariatric surgery by sleeve gastrectomy
for clinical indications according to current guidelines of
the Bariatric Scientific Collaborative Group and the
American Pediatric Surgical Association [23, 24]. We
obtained serum samples before and 6 months after surgery
in all patients.
Exercise intervention cohort Fifteen young healthy, lean
adults (ESM Table 3) participated in a 6 month exercise
programme consisting of sessions on 3 days of the
week. Each training session included 20 min biking or
running, 45 min circuit training and 20 min warming-up
and cooling-down periods. At baseline and after
6 months of training, blood samples were obtained in
the fasting state.
In all cohorts, height was measured to the nearest 0.1 cm
and weight to the nearest 0.1 kg using a digital balance. In
children, BMI data were standardised by age and sex
applying German reference data [25], and given as the
BMI standard deviation score (SDS). A cutoff of ≥1.23
and ≥1.88 SDS (90th and 97th centile) classified the
children as being overweight or obese. Detailed inclusion
criteria for all cohorts are given in supplementary methods
(see ESM Methods).
Written informed consent was obtained from all parents
and from children ≥12 years. All studies were approved
by the local ethics committees of the Universities of
Leipzig and Witten/Herdecke (reg. nos.: 782-1998
(schoolchildren), 029-2006 (Atherobesity cohort), 341-1
(adolescent bariatric surgery), 031-2006 (adult bariatric
surgery), 274-2008 (exercise study), 64/2001 and 15/2006
(‘Obeldicks’).
Quantification of endothelial progenitor cells in peripheral
blood
Endothelial progenitor cells (EPCs) were determined as
CD34 and kinase insert domain receptor (KDR) double-
positive cells applying flow cytometry [26] (Beckman
Coulter Epics XL, Krefeld, Germany). Number of EPCs is
given as EPCs per 500,000 counted cells.
Isolation, cultivation and stimulation of leucocytes
and subpopulations
Cells were isolated applying density gradient centrifugation
(Biocoll Separating Solution, Biochrom, Germany) of
20 ml peripheral blood from 12 children and adolescents
(age, 11.7±2.7 years; BMI SDS, 2.14±1.12). An incuba-
tion step of 2 h at 37°C in RPMI medium containing 0.5%
FCS, penicillin and streptomycin (culture medium [CM])
was used for separation of monocytes and lymphocytes.
Cell fractions were cultivated in CM for 6 h at 37°C before
harvesting of cells and supernatant fractions. Cell integrity
was confirmed by Trypan Blue staining and lactase
dehydrogenase assay (BIOCAT, Heidelberg, Germany).
For stimulation experiments, granulocytes and mono-
cytes were incubated in CM supplemented with 1 μg/ml
lipopolysaccharide (LPS; Sigma), 40 mmol/l D-glucose and
40 mmol/l L-glucose as osmotic control for 24 h at 37°C
before harvesting of cells and supernatant fractions.
In addition, leucocytes were isolated from peripheral
blood after oral glucose provocation at 0, 60 and 120 min,
and cultivated in CM for 45 min before harvest of cells and
supernatant fractions.
Analysis of NAMPT and SIRT1 mRNA expression
We obtained commercially available tissue RNAs (Clontech-
Takara Bio Europe, Saint-Germain-en-Laye, France) and
cDNAs (Biochain, Heidelberg, Germany). RNA from cell
fractions was extracted using the RNeasy Mini kit (Qiagen,
Hilden, Germany). Reverse transcription was performed
using 200 U M-MLV reverse transcriptase per microgram
total RNA with oligo (dT) primers. NAMPT and SIRT1
mRNA expression was determined using quantitative real-
time PCR with TaqMan probe-based gene expression assay
on the ABI 7500 Sequence Detection System (Applied
Biosystems, Darmstadt, Germany). To normalise gene
expression, housekeeping genes beta actin (ACTB), TBP
and HPRT were quantified simultaneously in each sample.
Quantification of NAMPT and enzyme activity in serum
samples, cell lysates and supernatant fractions
NAMPT concentrations were measured by ELISA follow-
ing the manufacturer’s protocol (Adipogen, Seoul, South
Korea). Assay quality variables including sensitivity and
specificity have been validated previously [27]. NAMPT
amounts in cell lysates and supernatant fractions were
1202 Diabetologia (2011) 54:1200–1211normalised to total protein amount (BCA Protein Assay,
Thermo Fisher Scientific, Bonn, Germany).
Preparation of samples and determination of enzymatic
activity were performed according to the method by Elliott et
al. [28] with minor modifications [12, 28]( s e eE S MMethods).
Statistical analyses
Logarithmic transformation of non-normally distributed
data was performed before analysis. For comparison of
quantitative traits between two groups, two-tailed Student’s
t test was applied. For more groups and time courses
ANOVA was applied, and for categorical data χ
2 test was
applied. Correlation analyses were performed using Pearson
correlation analysis or partial correlation analysis with
adjustment for BMI SDS. For multiple regression analyses,
the stepwise forward model was employed. For all tests, the
significance level was set at 0.05. Statistical analyses were
performed using the software package Statistica 7.1
(StatSoft, Tulsa, OK, USA).
Results
Association of NAMPT with normal development
in healthy lean children
We identified no differences in circulating NAMPT levels
with progression through puberty in normal healthy lean boys
or girls (ESM Fig. 1a). Also, there was no correlation
between NAMPT levels and height SDS, circulating IGF-I
and markers of pubertal development and adrenarche,
including oestradiol, testosterone or dehydroepiandrosterone-
sulfate (DHEA-S). There were no differences between boys
and girls in the entire cohort (ESM Fig. 1b) or if analysis was
restricted to adolescent children.
Association of NAMPT with obesity and obesity
interventions
We applied the Leipzig Atherobesity Childhood cohort
(ESM Table 2) to evaluate differences in NAMPT serum
concentrations between lean and obese children. NAMPT
levels were significantly higher in the obese children
compared with lean controls (Fig. 1a). NAMPT levels
correlated with BMI (Fig. 1b) and other variables of obesity
and body fat, including BMI SDS as a normalised index of
the degree of overweight, leptin as a biomarker of fat mass,
and skinfold thickness as an index of subcutaneous fat
(Table 1).
We further assessed NAMPTserum concentrations in the
context of three distinct intervention studies: (1) a 12 month
lifestyle intervention programme in children and adoles-
cents; (2) bariatric surgery by sleeve gastrectomy in
severely obese adolescents and adults; and (3) a 6 month
exercise intervention in normal weight young healthy adults
(ESM Table 3). The strategies differed in the extent of
weight loss and improvement of HOMA-IR achieved
(Fig. 1c, ESM Table 3).
After both the bariatric surgery and the exercise
interventions we found significantly lower NAMPT serum
concentrations, whereas we observed no significant change
after lifestyle intervention (Fig. 1c). The decrease in
NAMPT correlated significantly with the decrease in BMI
in the surgery group only (ESM Fig. 2d).
In addition to BMI, the bariatric surgery group showed
the strongest decrease in white blood cell count (WBC) and
high-sensitivity C-reactive protein (hsCrP; ESM Fig. 2a–c)
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Fig. 1 NAMPT association with obesity. a Obese children (n=86)
had significantly higher NAMPT levels (p=0.031) compared with
lean children (n=70). Data are mean ± SEM. b NAMPT serum levels
correlated with BMI (r=0.35, p<0.001). c Changes of NAMPT
levels and BMI after 1-year lifestyle intervention in obese children
and adolescents (n=36), 6 months following bariatric surgery in
severely obese adults and adolescents (n=14), and 6 month exercise
programme in normal weight adults (n=15). Data for BMI
(open bars) and NAMPT levels (black bars) are given relative to
the basal situation (hatched bar), which was set to 1.0. Data are mean
± SEM. Statistical significance was assessed by paired t test.
*p<0.05, **p<0.01, ***p<0.001
Diabetologia (2011) 54:1200–1211 1203and there was a significant correlation between decrease in
hsCrP and NAMPT in this group (ESM Fig. 2f). In multiple
regression analyses, decrease in hsCrP (β=0.65, p=0.033)
and decrease in BMI (β=0.86, p=0.029) were significant
predictors for the NAMPT decrease, whereas decrease in
WBC and basal WBC, hsCrP and BMI did not contribute
(R
2=0.83, p=0.035 for the model).
Association of NAMPT with glucose metabolism
NAMPT significantly correlated with all variables of
glucose and insulin metabolism (Table 1, Fig. 2a, b).
Children with impaired insulin sensitivity had higher
NAMPT levels compared with normal insulin-sensitive
children (Fig. 2c). When we adjusted for BMI SDS in
partial correlation analyses, only mean blood glucose (BG)
and AUC BG as dynamic variables during OGTT remained
significant, but most other significances were lost (Table 1).
In multiple regression analyses, NAMPT was significantly
associated with AUC BG (β=0.24±0.08, p=0.004), where-
as BMI SDS, age, sex and pubertal stage did not contribute
significantly.
To investigate this finding in more detail, we analysed
the dynamic of NAMPT serum concentrations during an
OGTT in 24 obese adolescents (age 11.7±4.1 years, BMI
SDS 2.60±0.53). Compared with basal levels, NAMPT
levels declined to 77±0.1% (p=0.0029). This decline was
stronger in the insulin-sensitive obese participants, as
evidenced by a negative correlation of NAMPT with
Matsuda ISI (Fig. 2d). We thus stratified groups into
insulin-resistant and insulin-sensitive patients on the basis
of peak insulin during OGTT >1,000 and <600 pmol/l,
respectively (Fig. 2e, f). Accordingly, Matsuda ISI was
significantly impaired in the hyperinsulinaemic group
(8.02±0.70 vs 2.59±0.29, p<0.0001). There was no
difference in the degree of obesity between the two groups
Variable Univariate correlation Partial correlation
rp value r
a p
a value
Anthropometric variables
BMI SDS 0.31 <0.0001
BMI (kg/m
2) 0.35 <0.0001
Serum leptin (ng/ml)
b 0.25 0.007
WHR 0.06 0.426
Skinfold thickness (cm) 0.31 <0.0001
Metabolic variables
Fasting BG (mmol/l) 0.26 0.001 0.07 0.401
120 min BG (mmol/l) 0.20 0.012 0.13 0.129
Mean BG (mmol/l) 0.25 0.001 0.21 0.009
AUC BG (mmol/l × min) 0.28 <0.0001 0.23 0.004
FPI
b (pmol/l) 0.26 0.001 0.08 0.346
Peak insulin
b (pmol/l) 0.24 0.003 0.10 0.237
AUCIns
b (pmol/l × min) 0.27 0.001 0.13 0.124
HOMA-IR
b 0.23 0.004 0.11 0.395
Matsuda ISI
b −0.29 <0.0001 −0.09 0.112
Belfiore ISI −0.31 <0.0001 −0.19 0.021
AUCIns/AUCBG (pmol/mmol) 0.24 0.003 0.10 0.215
Cardiovascular variables
Systolic BP (mmHg) 0.20 0.012 0.09 0.241
Diastolic BP (mmHg) 0.09 0.226 0.03 0.676
Mean systolic BP in 24 h (mmHg) 0.18 0.043 0.06 0.491
Mean diastolic BP in 24 h (mmHg) 0.10 0.247 0.06 0.515
IMT (cm) 0.11 0.174 −0.04 0.582
Endothelial function (RHI) −0.23 0.004 −0.10 0.232
EPC count (per 50,0000 counts)
b −0.29 <0.0001 −0.25 0.002
EPC migration
b 0.01 0.871 0.04 0.669
WBC count (×10
9/l)
b 0.49 <0.0001 0.44 <0.0001
hsCrP (ng/ml)
b 0.34 <0.0001 0.27 0.001
Table 1 Association of
NAMPT levels with
anthropometric, metabolic and
cardiovascular variables in lean
and obese children of the
Leipzig Atherobesity Childhood
cohort (n=156)
Pearson correlation analysis was
performed for log-transformed
NAMPT serum levels, n=156
BP, blood pressure; FPI, fasting
plasma insulin; Ins, insulin
aPearson partial correlation
analysis adjusted for BMI SDS
bIndicates log-transformed
variables
1204 Diabetologia (2011) 54:1200–1211(2.72±0.11 vs 2.48±0.20 BMI SDS, p>0.2). The decline of
NAMPT, however, was significantly more pronounced in the
insulin-sensitive group (Fig. 2g) and correlated with AUC-
insulin-to-AUC-BG ratio (r=0.43, p=0.038). Likewise,
individual NAMPT levels during OGTT correlated with the
insulin-to-glucose ratio at each time point (r=−0.19,
p=0.034). Thus, NAMPT levels declined after an oral
glucose load as a function of time and insulin-to-glucose
ratio (Fig. 2h).
Association of NAMPT with cardiovascular parameters
and leucocytes
We assessed the correlation of NAMPT levels with cardio-
vascular variables (random and 24 h blood pressure),
functional variables of early vascular impairment (IMT,
endothelial function), and regenerative capacity (EPC count
andmigratoryfunction)inourAtherobesityChildhoodcohort.
We identified significant correlations of NAMPTwith systolic
blood pressure and endothelial function that did, however, not
withstand adjustment for BMI SDS in partial correlation
analyses (Table 1). By contrast, the cellular variables EPC
and WBC counts, and hsCrP, were significantly associated
with NAMPT serum levels (Fig. 3a, b, Table 1). In multiple
regression analyses, NAMPT was the strongest predictor for
E P Ca sw e l la sf o rW B Cc o u n t s( T a b l e2).
Considering this predominant association of NAMPT
with WBCs, we hypothesised that WBCs may influence the
associations of NAMPT with metabolic variables and
evaluated the correlation of WBCs themselves with
metabolic and cardiovascular variables. We identified
significant BMI-independent correlations with AUC insu-
lin, Matsuda ISI (Fig. 3c, d), systolic blood pressure
(r=0.18, p=0.024), but most strongly with NAMPT serum
levels (Fig. 3e). Likewise, in multiple regression analyses,
WBCs contributed significantly and independently of age,
sex and BMI SDS to Matsuda ISI (Table 2).
Hence, NAMPT is most strongly associated with WBC
count and WBCs themselves are significantly associated
with variables of insulin resistance.
Expression pattern of NAMPT in tissues and leucocytes
Considering the strong association of circulating NAMPT
levels with leucocytes in the clinical study, we systemati-
cally evaluated the expression pattern of NAMPT among
14 metabolically, endocrine and immunologically active
tissues. We found that NAMPT mRNA was predominantly
expressed in peripheral blood leucocytes (Fig. 4a).
To determine which subpopulation(s) of leucocytes
potentially contribute to NAMPT levels in peripheral blood,
we assessed NAMPT mRNA and NAMPT protein expres-
sion in granulocytes, lymphocytes and monocytes isolated
from peripheral blood of 12 children and adolescents. The
mRNA expression was more than fivefold higher in
granulocytes and monocytes compared with lymphocytes
(Fig. 4b). Consistent with this, we detected a higher amount
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Fig. 2 NAMPT association with glucose/insulin metabolism.
Correlation of NAMPT serum levels with AUC BG during OGTT
(a)( r=0.25, p=0.001) and Matsuda ISI (b)( r=−0.29, p<0.001).
White circles = lean children, black circles = obese children.
c Children with impaired insulin sensitivity according to Matsuda
ISI<4 (n=44) had higher NAMPT levels compared with normal
insulin sensitivity (n=105, p=0.003). Data are given as mean ± SEM
and were analysed by t test of log-transformed NAMPT. d
Correlation of NAMPT decline (given as mean ratio of NAMPT
between 60–120 min to basal NAMPT) and Matsuda ISI (r=0.48,
p=0.017). Course of blood glucose (e), insulin (f) and NAMPT (g)
serum levels during OGTT in insulin-sensitive (n=11) and insulin-
resistant (n=13) obese children. For NAMPT, data are given as ratio
of NAMPT levels at single time points compared with basal NAMPT
at t=0 (pAnova=0.003). White circles, normal insulin; black circles,
hyperinsulinemia. h Three-dimensional plot of NAMPTas a function
of insulin-to-glucose ratio and time during OGTT
Diabetologia (2011) 54:1200–1211 1205of NAMPT protein in cell lysates of granulocytes and
monocytes compared with lymphocytes (Fig. 4c). Granulo-
cytes secreted highest amounts of NAMPT protein into cell
culture supernatant fractions (Fig. 4d). Consistently, serum
concentrations of NAMPT were highly correlated to
leucocyte count, particularly to neutrophil granulocyte and
monocyte count but not to lymphocyte count (Fig. 4e–g).
Hence, NAMPT is predominantly produced and secreted by
leucocytes, in particular by granulocytes.
NAMPT function and interaction with SIRT1 and LPS
in distinct leucocyte subpopulations
We evaluated the enzymatic activity of the NAMPT protein
by quantification of nicotinamide mononucleotide (NMN)
synthesis from nicotinamide and confirmed that NAMPT
enzymatic activity was present in cell lysates and superna-
tant fractions of all leucocyte subpopulations (Fig. 4h).
To assess a downstream target of NAMPT activity, we
examined SIRT1 mRNA expression in the leucocyte
subpopulations. The expression of SIRT1 was significantly
higher in granulocytes compared with lymphocytes and
monocytes (Fig. 4i).
To finally evaluate whether NAMPT is stimulated by
inflammatory agents, we analysed NAMPT release follow-
ing stimulation with LPS. LPS significantly increased
NAMPT release from monocytes and slightly enhanced
NAMPT release from granulocytes (Fig. 4j).
Leucocyte counts and NAMPT release from leucocytes
during OGTT
We assessed whether the decline of NAMPT during OGTT
is attributable to reduced leucocyte counts or reduced
NAMPT release from leucocytes in 11 additional patients.
The leucocyte, lymphocyte and neutrophil counts did not
change significantly after oral glucose intake; only mono-
cytes were significantly decreased after 60 min (ESM
Fig. 3a). Ex vivo, we found a slight decrease in NAMPT
release after 120 min (ESM Fig. 3b). Finally, to assess
whether glucose has a direct effect on NAMPT release, we
incubated isolated leucocytes with glucose, but we did not
find significant changes (ESM Fig. 3c).
Discussion
In this study, we showed that NAMPT is not only
associated with obesity and glucose metabolism, but has
the strongest relationship with leucocyte count and is in fact
predominantly produced in leucocytes in its enzymatically
active form. The circulating leucocyte count strongly
correlated to insulin resistance, and the association of
NAMPT with obesity and glucose metabolism may reflect
an underlying relation with leucocytes.
Circulating NAMPT is affected by obesity and obesity
intervention
NAMPT has drawn considerable interest in the fields of
obesity, type 2 diabetes and inflammatory diseases. Some
studies reported that circulating NAMPT is elevated in
obesity and type 2 diabetes [8, 10], whereas others found
no association with adiposity and metabolic variables [9].
In our study, circulating NAMPT was significantly higher
in obese compared with lean children, and correlated with
the extent of obesity. If NAMPT is related to obesity, one
would expect a decrease after weight loss, as has been
1.0 1.5 2.0 2.5 3.0
Log WBC (×109/l)
−1
0
1
2
3
4
L
o
g
 
M
a
t
s
u
d
a
 
I
S
I
1.0 1.5 2.0 2.5 3.0
WBC (×109/l)
9
10
11
12
13
14
L
o
g
 
A
U
C
 
i
n
s
u
l
i
n
 
(
p
m
o
l
/
l
 
×
 
m
i
n
)
1.0 1.5 2.0 2.5 3.0
WBC (×109/l)
−0.5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
L
o
g
 
N
A
M
P
T
−10 1 23
Log NAMPT (ng/ml)
−1
0
1
2
3
4
L
o
g
 
E
P
C
/
5
0
0
,
0
0
0
−2 −10 1 2 3
Log NAMPT (ng/ml)
−6
−4
−2
0
2
4
6
L
o
g
 
h
s
C
r
P
 
(
n
g
/
m
l
)
ac
b d
e
Fig. 3 NAMPT association with leucocytes in the Leipzig Atherobe-
sity Childhood cohort. Correlation of NAMPT serum levels with EPC
count (a)( r=−0.29, p<0.001) and hsCrP (b)( r=0.34, p<0.001).
Correlations of WBC count with metabolic variables AUC insulin (c)
(r=0.35, p<0.001) and Matsuda ISI (d)( r=−0.33, p<0.001). The
strongest correlation was achieved between NAMPT and WBC count
(e)( r=0.46, p<0.001). White circles, lean children; black circles,
obese children. Correlation coefficients were determined by Pearson
correlation analyses of log-transformed variables
1206 Diabetologia (2011) 54:1200–1211shown by some studies [8, 29, 30]. We show that NAMPT
was reduced by significant weight loss after bariatric
surgery but not by moderate weight loss due to lifestyle
intervention. Exercise was also successful in reducing
NAMPT levels as well as improving insulin sensitivity.
Interestingly, bariatric surgery and exercise led to a
concomitant reduction in WBC and hsCrP, and the decrease
in NAMPT not only correlated with the decrease in BMI
but also with the decrease in hsCrP. This suggests that in
addition to a significant reduction in adipose tissue mass and/
or insulin resistance, improvement in the inflammatory state
may account for a reduction of NAMPT by interventions.
Circulating NAMPT declines after oral glucose provocation
NAMPT was associated with metabolic variables in our
study. However, when analyses were adjusted for the
degree of obesity, most associations were abolished, thus
indicating that the correlation with insulin resistance was
mainly secondary to obesity. Only dynamic variables of
blood glucose during an OGTT remained significant after
adjustment for BMI. Considering this finding, and that
NAMPT has been shown to play a crucial role in beta cell
function [5], we investigated the acute response of NAMPT
to oral glucose provocation. As NAMPT has been reported
to be increased by hyperglycaemia through i.v. glucose
infusions and experimentally in adipocytes [31], one may
expect an increase of NAMPT during an OGTT. Surpris-
ingly, NAMPT levels declined following glucose challenge.
Our results contrast with the findings of other studies,
which reported a transient increase of NAMPT [32] or have
failed to demonstrate any NAMPT response during an
OGTT [33]. These contrasting findings may result from
different patient characteristics, specifically the distinct
degree of obesity, stratification for glucose vs for insulin
resistance study, and in particular from the fact that all
previous studies were performed in adults, whereas we
investigated children. Children are at the beginning of the
pathophysiologic development of insulin resistance and less
biased by co-morbidities and their treatment; they may
hence allow a better exploration of a potential association
of NAMPT with glucose metabolism. Also different
analytical methods need to be considered that have been
shown to have a crucial impact on the quantification of
NAMPT/visfatin [27].
In our study, the decline of NAMPT was a function of
time and insulin-to-glucose ratio. Time was the strongest
predictor for the change of NAMPT serum concentration
after glucose provocation. This may indicate that the natural
circadian variation may affect NAMPT. A rhythmic
oscillation in mRNA and protein levels of NAMPT was
recently discovered [34, 35]. However, considering that: (1)
NAMPT is lower with higher insulin-per-glucose secretion
in our study; (2) our in vitro findings that did not show a
Table 2 Multiple regression analyses for independent associations of NAMPT serum levels
Step Variable R
2 β ± SEM B ± SEM p value
Dependent variable: log EPC count
a
1 log NAMPT 0.08 −0.22±0.10 −0.23±0.10 0.023
2 Leptin 0.03 −0.16±0.10 −0.007±0.004 0.095
3 Systolic BP SDS 0.01 −0.12±0.09 −0.07±0.06 0.197
Dependent variable: log WBC count
b
1 log NAMPT 0.240 0.35±0.08 0.15±0.03 <0.001
2 log AUCIns 0.105 0.40±0.10 0.19±0.05 <0.001
3 log EPC count 0.022 −0.16±0.08 −0.06±0.03 0.045
4 Leptin 0.015 −0.21±0.10 −0.003±0.002 0.046
5 log hsCrP 0.014 0.13±0.09 0.02±0.01 0.124
Dependent variable: log Matsuda ISI
c
1 BMI SDS 0.360 −0.54±0.06 −0.23±0.03 <0.001
2 log WBC 0.070 −0.26±0.06 0.56±0.14 <0.001
3 Age 0.032 −0.17±0.06 −0.03±0.01 0.006
4 Sex 0.008 0.09±0.06 0.11±0.07 0.140
Ins, insulin; PH, pubic hair stage
aR
2 =0.12, p=0.0019 (Childhood Atherobesity cohort, n=156). Independent variables: BMI SDS, leptin, systolic BP SDS, log AUCIns, log ISI, log hsCrP,
log NAMPT
bR
2 =0.40, p<0.0001(Childhood Atherobesity cohort, n=156). Independent variables: BMI SDS, leptin, systolic BP SDS, log AUCIns, log ISI, log hsCrP,
log NAMPT, log EPC count
cR
2 =0.47, p<0.0001(Childhood Atherobesity cohort, n=156). Independent variables: BMI SDS, log NAMPT, log WBC, age, sex, PH
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Fig. 4 NAMPT expression pattern, production and secretion by
leucocyte subpopulations. a The expression of NAMPT mRNA was
significantly higher in PBL than in all other tissues, including adipose
tissue and liver (pAnova<0.0001). Significance was calculated by one-
way ANOVA with Dunnett’s post test (compared with PBL). b The
mRNA expression of NAMPT was more than fivefold higher in
granulocytes and monocytes compared with lymphocytes. c Higher
amounts of NAMPT protein were detected in cell lysates of
granulocytes and monocytes compared with lymphocytes. d Gran-
ulocytes secreted more than 22-fold higher amounts of NAMPT
protein into cell culture supernatant fractions (n=12) when normalised
to total protein. Serum concentrations of NAMPT were highly
correlated to leucocyte count in particular to neutrophil granulocyte
(e)( r=0.92, p=0.009) and monocyte (f)( r=0.94, p=0.005) count but
not to lymphocyte count (g)( n=6, p=0.41). h NAMPT enzymatic
activity was present in cell lysates and supernatant fractions of all
leucocyte subpopulations (n=5). i SIRT1 mRNA expression was
significantly higher in granulocytes compared with lymphocytes and
monocytes (n=12). j The release of NAMPT was significantly
increased from monocytes and granulocytes after stimulation with
1 μg/ml LPS for 24 h in n=3 independent experiments. Data are mean
± SEM. Statistical significance was assessed by Student’s t test and
Pearson correlation analysis: *p<0.05, **p<0.01, ***p<0.0001. G,
granulocytes; L, lymphocytes; M, monocytes; PBL, peripheral blood
leucocytes
1208 Diabetologia (2011) 54:1200–1211stimulation of NAMPT release by glucose; and (3) the
proposed role for NAMPT in beta cell function [5], one may
conclude that NAMPT augments glucose stimulated insulin
secretion and is then negatively regulated by insulin. This
feedback regulation seems to be disturbed in insulin-resistant
participants, as the decline in NAMPT is predominant in
insulin-resistant participants [10, 36]. In addition, other
groups provided evidence that glucose directly downregu-
lates NAMPT production in different cell types [37, 38].
Hence, the glucose stimulus and/or resulting insulin release
and/or natural circadian variations in NAMPT levels may
contribute to the decline of NAMPT in OGTT, although the
precise mechanisms remain unclear at this point.
NAMPT is produced and secreted by leucocyte
subpopulations
In our cross-sectional study, we found the strongest
independent associations of circulating NAMPT with
leucocyte counts. As there is no systematic evaluation of
the origin of NAMPT so far, this prompted us to evaluate
NAMPT expression among several metabolically, endocrine
and immunologically active tissues. We found highest
amounts of NAMPT mRNA in leucocytes compared with
all other tissues, including adipose tissue and liver. Higher
expression of NAMPT in non-fat cells and adipose tissue
derived macrophages compared with fat cells has been
reported before [11, 39], further supporting the hypothesis
that adipose tissue is not the major source of NAMPT. We
subsequently evaluated which leucocyte subpopulation(s)
may account for the high NAMPT production and found
that NAMPT mRNA expression was higher in granulocytes
and monocytes compared with lymphocytes, and that
granulocytesreleased significantly moreNAMPT protein into
cell culture supernatant fractions. Considering that neutrophil
granulocytes constitute 50% to 60% of the total circulating
WBCs, we hypothesise that granulocytes represent a major
source of circulating NAMPT. To our knowledge, none of the
previous clinical studies have adjusted their analyses for
leucocyte counts, which may contribute to the conflicting
results reported in the clinical studies so far.
NAMPT as a marker of low grade inflammation in obesity
Given that leucocytes are a major source of circulating
NAMPT, one may hypothesise that the increase of NAMPT
in obese participants [40, 41] may be related to low-grade
inflammation seen in obesity. This is substantiated by the
association of NAMPT with inflammatory markers ob-
served here, and in other studies [42]. In addition, we
demonstrated that LPS stimulated NAMPT production in
monocytes and granulocytes, which is in line with a new
study showing that NAMPT is induced in human macro-
phages [43]. Taken together, this suggests a role for
NAMPT and immune cells in chronic low grade inflamma-
tion observed in obesity and type 2 diabetes. These findings
also indicate that the association of NAMPT with obesity
and type 2 diabetes may be partly secondary to an
underlying association of NAMPT with leucocytes.
This may in consequence have an impact on downstream
targets, such as the NAD consuming factor SIRT1, which in
turn has been shown to exert antiapoptotic effects [3].
Supporting this hypothesis, SIRT1 mRNA expression was
significantly higher in granulocytes in our study, which may
suggest that increased NAMPT levels delay apoptosis of
granulocytes in obesity via induction of SIRT1. Another
recent study has shown that NAMPT-mediated NAD biosyn-
thesisplays a crucial rolein myeloid differentiationinhumans
[44]. These results may further explain the high correlation
between circulating NAMPT and leucocyte counts, in that
the high NAMPT levels may promote myeloid differentia-
tion through SIRT1 and eventually increase the number of
peripheral blood leucocyte counts. This would indicate that
there is a mechanistic link between circulating NAMPT and
leucocyte counts, and this may in consequence be relevant
for the obesity-related increase in inflammatory status.
Leucocytes as major source of NAMPT: clinical
implications
Our major new finding is that NAMPT is predominantly
produced by leucocytes, independent from BMI. Interest-
ingly, the decline of NAMPT after weight loss due to
bariatric surgery, exercise [45], and glucose provocation
[46] was paralleled by a decline in leucocyte counts.
Furthermore we show that leucocytes per se, and independent
from BMI, are associated with insulin sensitivity markers in
obese children. Hence we speculate that this direct link
betweenNAMPTandleucocytesmayunderlietheassociation
between NAMPT and obesity and insulin resistance, and in
particular the low-grade inflammatory state seen in these
conditions.Thereissupportforthisnotionfromrecentstudies
showing that NAMPT is related with systemic inflammation
in diabetic patients [47], that NAMPT serum concentrations
and mRNA expression levels in leucocytes are increased in
obese patients and that plasma NAMPT levels are related to
inflammation in fatty liver disease [48]. Finally, NAMPT
was one of five markers that discriminated between patients
with chronic inflammation and healthy controls [49].
In summary, we not only provide clinical evidence on the
association of NAMPT with obesity and obesity-related
metabolic and cardiovascular sequelae in children, but show
that NAMPT is acutely downregulated after glucose provoca-
tion. In particular, we identified leucocytes as a major source
of enzymatically active NAMPT and reveal that the associa-
tionofcirculatingNAMPTwithleucocytecountoutrangesthe
Diabetologia (2011) 54:1200–1211 1209one withobesity.Thisfindingmaybeofparticularimportance
linkingobesity,inflammationandinsulinresistance,forwhich
NAMPT may be a marker or even a mediator.
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